Selective treatment and monitoring of disseminated cancer micrometastases in vivo using dual-function, activatable immunoconjugates

Proceedings of the National Academy of Sciences of the United States of America

Volumn 111, Issue 10, 2014, Pages

  Springa, Bryan Q ^a   Abu Yousif, Adnan O ^a   Palanisami, Akilan ^a   Rizvi, Imran ^a   Zheng, Xiang ^a   Mai, Zhiming ^a   Anbil, Sriram ^a   Sears, R Bryan ^a,c   Mensah, Lawrence B ^a   Goldschmidt, Ruth ^a   Erdem, S Sibel ^a   Oliva, Esther ^a   Hasan, Tayyaba ^a,b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b HARVARD UNIVERSITY   (United States)

^c EMMANUEL COLLEGE   (United States)

Author keywords

Activatable imaging agent; Activatable therapeutic agent; Molecular imaging; Ovarian cancer; Photodynamic therapy

Indexed keywords

ANTIBODY CONJUGATE; BENZOPORPHYRIN DERIVATIVE; CANCER ANTIBODY; CETUXIMAB; CISPLATIN; PACLITAXEL; VERTEPORFIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CARCINOMATOUS PERITONITIS; CHROMATOPHORE; CONTROLLED STUDY; CYTOTOXICITY; DISSEMINATED CANCER; FEMALE; IMMUNOTHERAPY; IN VIVO STUDY; INTERNALIZATION; MICROMETASTASIS; MOUSE; NONHUMAN; PHOTOACTIVATION; PHOTOTOXICITY; PRIORITY JOURNAL;

ACTIVATABLE IMAGING AGENT; ACTIVATABLE THERAPEUTIC AGENT; MOLECULAR IMAGING; OVARIAN CANCER; PHOTODYNAMIC THERAPY;

ANIMALS; ANTIBODIES, MONOCLONAL; DRUG DELIVERY SYSTEMS; ENDOSCOPY; FEMALE; FLUORESCENCE; IMMUNOCONJUGATES; IMMUNOTHERAPY; LIGHT; MICE; MONITORING, IMMUNOLOGIC; NEOPLASM MICROMETASTASIS; OVARIAN NEOPLASMS; PHOTOTHERAPY; SENSITIVITY AND SPECIFICITY;

EID: 84896265113     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1319493111     Document Type: Article

References (56)

1. Naora H, Montell DJ (2005) Ovarian cancer metastasis: Integrating insights from dis parate model organisms. Nat Rev Cancer 5(5):355-366.
2. Bast RC, Jr., Hennessy B, Mills GB (2009) The biology of ovarian cancer: New oppor tunities for translation. Nat Rev Cancer 9(6):415-428.
3. Pantel K, Alix-Panabières C, Riethdorf S (2009) Cancer micrometastases. Nat Rev Clin Oncol 6(6):339-351.
4. Lengyel E (2010) Ovarian cancer development and metastasis. Am J Pathol 177(3): 1053-1064.
5. Nguyen DX, Bos PD, Massagué J (2009) Metastasis: From dissemination to organ-specific colonization. Nat Rev Cancer 9(4):274-284.
6. Glehen O, et al. (2004) Cytoreductive surgery combined with perioperative in-traperitoneal chemotherapy for the management of peritoneal carcinomatosis from colorectal cancer: A multi-institutional study. J Clin Oncol 22(16):3284-3292.
7. Hidalgo M (2010) Pancreatic cancer. N Engl J Med 362(17):1605-1617.
8. Meirelles K, et al. (2012) Human ovarian cancer stem/progenitor cells are stimulated by doxorubicin but inhibited by Mullerian inhibiting substance. Proc Natl Acad Sci USA 109(7):2358-2363.
9. Selman AE, Copeland LJ (1999) The roles of second-look laparotomy and cancer an tigen 125 in the management of ovarian carcinoma. Curr Oncol Rep 1(1):71-76.
10. Gadducci A, et al. (2007) Surveillance procedures for patients treated for epithelial ovarian cancer: A review of the literature. Int J Gynecol Cancer 17(1):21-31.
11. Soussan M, et al. (2012) Comparison of FDG-PET/CT and MR with diffusion-weighted imaging for assessing peritoneal carcinomatosis from gastrointestinal malignancy. Eur Radiol 22(7):1479-1487.
12. del Carmen MG, etal. (2005)Synergism of epidermal growth factor receptor-targeted immunotherapy with photodynamic treatment of ovarian cancer in vivo. J Natl Cancer Inst 97(20):1516-1524.
13. Kessel D (2006) Death pathways associated with photodynamic therapy. Med Laser Appl 21(4):219-224.
14. Castano AP, Mroz P, Hamblin MR (2006) Photodynamic therapy and anti-tumour immunity. Nat Rev Cancer 6(7):535-545.
15. van Dam GM, et al. (2011) Intraoperative tumor-specific fluorescence imaging in ovarian cancer by folate receptor-α targeting: First in-human results. Nat Med 17(10): 1315-1319.
16. Stummer W, et al. (2006) Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: A randomised controlled multicentre phase III trial. Lancet Oncol 7(5):392-401.
17. Nguyen QT, et al. (2010) Surgery with molecular fluorescence imaging using activatable cell-penetrating peptides decreases residual cancer and improves survival. Proc Natl Acad Sci USA 107(9):4317-4322.
18. Mew D, Wat CK, Towers GH, Levy JG (1983) Photoimmunotherapy: Treatment of animal tumors with tumor-specific monoclonal antibody-hematoporphyrin con jugates. J Immunol 130(3):1473-1477.
19. Goff BA, Bamberg M, Hasan T (1991) Photoimmunotherapy of human ovarian car cinoma cells ex vivo. Cancer Res 51(18):4762-4767.
20. Duska LR, Hamblin MR, Miller JL, Hasan T (1999) Combination photoimmunotherapy and cisplatin: Effects on human ovarian cancer ex vivo. J Natl Cancer Inst 91(18): 1557-1563.
21. Molpus KL, Hamblin MR, Rizvi I, Hasan T (2000) Intraperitoneal photoimmunotherapy of ovarian carcinoma xenografts in nude mice using charged photoimmunoconjugates. Gynecol Oncol 76(3):397-404.
22. Soukos NS, et al. (2001) Epidermal growth factor receptor-targeted immunophotodiagnosis and photoimmunotherapy of oral precancer in vivo. Cancer Res 61(11):4490-4496.
23. Rizvi I, et al. (2012) Photoimmunotherapy and irradiance modulation reduce che motherapy cycles and toxicity in a murine model for ovarian carcinomatosis: Per spective and results. Isr J Chem 52(8-9):776-787.
24. van Dongen GA, Visser GW, Vrouenraets MB (2004) Photosensitizer-antibody con jugates for detection and therapy of cancer. Adv Drug Deliv Rev 56(1):31-52.
25. Mitsunaga M, et al. (2011) Cancer cell-selective in vivo near infrared photo immunotherapy targeting specific membrane molecules. Nat Med 17(12): 1685-1691.
26. Celli JP, Solban N, Liang A, Pereira SP, Hasan T (2011) Verteporfin-based photody namic therapy overcomes gemcitabine insensitivity in a panel of pancreatic cancer cell lines. Lasers Surg Med 43(7):565-574.
27. Hahn SM, et al. (2006) A phase II trial of intraperitoneal photodynamic therapy for patients with peritoneal carcinomatosis and sarcomatosis. Clin Cancer Res 12(8): 2517-2525.
28. Urano Y, et al. (2009) Selective molecular imaging of viable cancer cells with pH-activatable fluorescence probes. Nat Med 15(1): 104-109.
29. Lee H, et al. (2011) Near-infrared pH-activatable fluorescent probes for imaging pri mary and metastatic breast tumors. Bioconjug Chem 22(4):777-784.
30. Molpus KL, et al. (1996) Characterization of a xenograft model of human ovarian carcinoma which produces intraperitoneal carcinomatosis and metastases in mice. Int J Cancer 68(5):588-595.
31. Roberts D, et al. (2005) Identification of genes associated with platinum drug sensi tivity and resistance in human ovarian cancer cells. BrJ Cancer 92(6): 1149-1158.
32. Zhong W, et al. (2009) In vivo high-resolution fluorescence microendoscopy for ovarian cancer detection and treatment monitoring. Br J Cancer 101 (12):2015-2022.
33. Psyrri A, et al. (2005) Effect of epidermal growth factor receptor expression level on survival in patients with epithelial ovarian cancer. Clin Cancer Res 11 (24 Pt 1): 8637-8643.
34. Mendelsohn J, Baselga J (2003) Status of epidermal growth factor receptor antago nists in the biology and treatment of cancer. J Clin Oncol 21(14):2787-2799.
35. Savellano MD, Hasan T (2003) Targeting cells that overexpress the epidermal growth factor receptor with polyethylene glycolated BPD verteporfin photosensitizer immunoconjugates. Photochem Photobiol 77(4):431-439.
36. Abu-Yousif AO, et al. (2012) Epidermal growth factor receptor-targeted photosensi tizer selectively inhibits EGFR signaling and induces targeted phototoxicity in ovarian cancer cells. Cancer Lett 321 (2):120-127.
37. Savellano MD, Hasan T (2005) Photochemical targeting of epidermal growth factor receptor: A mechanistic study. Clin Cancer Res 11 (4): 1658-1668.
38. Cengel KA, Glatstein E, Hahn SM (2007) Intraperitoneal photodynamic therapy. Cancer Treat Res 134:493-514.
39. Molpus KL, et al. (1996) Intraperitoneal photodynamic therapy of human epithelial ovarian carcinomatosis in a xenograft murine model. Cancer Res 56(5):1075-1082.
40. Goff BA, Blake J, Bamberg MP, Hasan T (1996) Treatment of ovarian cancer with photodynamic therapy and immunoconjugates in a murine ovarian cancer model. BrJ Cancer 74(8):1194-1198.
41. Mohamed MM, Sloane BF (2006) Cysteine cathepsins: Multifunctional enzymes in cancer. Nat Rev Cancer 6(10):764-775.
42. Weissleder R, Tung CH, Mahmood U, Bogdanov A, Jr. (1999) In vivo imaging of tumors with protease-activated near-infrared fluorescent probes. Nat Biotechnol 17(4): 375-378.
43. Liu TW, et al. (2011) Imaging of specific activation of photodynamic molecular bea cons in breast cancer vertebral metastases. Bioconjug Chem 22(6):1021-1030.
44. Lovell JF, et al. (2011) Porphysome nanovesicles generated by porphyrin bilayers for use as multimodal biophotonic contrast agents. Nat Mater 10(4):324-332.
45. Reed JC, et al. (1996) BCL-2 family proteins: Regulators of cell death involved in the pathogenesis of cancer and resistance to therapy. J Cell Biochem 60(1):23-32.
46. Flusberg BA, et al. (2005) Fiber-optic fluorescence imaging. Nat Methods 2(12): 941-950.
47. Lüdicke F, et al. (2003) Photodynamic diagnosis of ovarian cancer using hexamino-laevulinate: A preclinical study. BrJ Cancer 88(11): 1780-1784.
48. Yelin D, etal. (2006) Three-dimensional miniature endoscopy. Nature 443(7113):765.
49. Hsiung P-L, et al. (2008) Detection of colonic dysplasia in vivo using a targeted heptapeptide and confocal microendoscopy. Nat Med 14(4):454-458, correction (2008) 14(5):585.
50. Kim P, et al. (2010) In vivo wide-area cellular imaging by side-view endomicroscopy. Nat Methods 7(4):303-305.
51. John R, et al. (2010) In vivo magnetomotive optical molecular imaging using targeted magnetic nanoprobes. Proc Natl Acad Sci USA 107(18):8085-8090.
52. Williams RM, et al. (2010) Strategies for high-resolution imaging of epithelial ovarian cancer by laparoscopic nonlinear microscopy. Transl Oncol 3(3):181-194.
53. Pierce MC, et al. (2012) A pilot study of low-cost, high-resolution microendoscopy as a tool for identifying women with cervical precancer. Cancer Prev Res (Phila) 5(11): 1273-1279.
54. Hagen N, Tkaczyk TS (2012) Foveated endoscopic lens. J Biomed Opt 17(2):021104.
55. Fauci JM, et al. (2011) Prognostic significance of the relative dose intensity of che motherapy in primary treatment of epithelial ovarian cancer. Gynecol Oncol 122(3): 532-535.
56. Mendelsohn J, Baselga J (2000) The EGF receptor family as targets for cancer therapy. Oncogene 19(56):6550-6565.